XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2023
Jan. 31, 2022
Aug. 31, 2018
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2023
Sep. 30, 2018
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Other Commitments [Line Items]                      
Contractual obligation is payable within 60 days       $ (50,000)       $ (50,000)      
Loss (gain) on strategic investment               0 $ 5,109    
Research and development       66,606 $ 156,963     202,518 284,878    
Restricted cash       8,770 $ 5,770     8,770 5,770 $ 5,770 $ 5,770
Letter of Credit | Corporate Credit Card Program                      
Other Commitments [Line Items]                      
Restricted cash       2,000       2,000      
Letter of Credit | Fleet Program                      
Other Commitments [Line Items]                      
Restricted cash       400       400      
Stoke Therapeutics, Inc. [Member] | Research and Development [Member]                      
Other Commitments [Line Items]                      
Collaborative Arrangements Upfront Consideration And Transaction Payment   $ 60,000                  
Mile stone payments payable   907,500                  
Upfront consideration and transaction costs   $ 60,000                  
Collaboration agreement description   For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits                  
License Agreements | North America                      
Other Commitments [Line Items]                      
Mile stone payments payable           $ 40,000          
License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Upfront payment $ 100,000                    
Mile stone payments payable       50,000       50,000      
Upfront license fee     $ 10,000                
Net sales               250,000      
Milestone payment as intangible asset           40,000          
PRV liability           $ 29,600          
License Agreements | Neuren | Research and Development [Member] | North America                      
Other Commitments [Line Items]                      
Upfront payment             $ 10,000   $ 100,000    
License Agreements | Neuren | Development Commercialization and Sales Milestones                      
Other Commitments [Line Items]                      
Upfront payment 831,300                    
Maximum                      
Other Commitments [Line Items]                      
Mile stone payments payable       $ 3,400,000       $ 3,400,000      
Maximum | License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Mile stone payments payable $ 426,300   $ 455,000